Nagui Gendi

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

Frances Humby, Patrick Durez, Maya H Buch et al. · The Lancet · 2021 · 315 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

Felice Rivellese, Anna E. A. Surace, Katriona Goldmann et al. · Nature Medicine · 2022 · 279 citations · Full text

Life Sciences, Immunology, Internal Medicine +17

Randomized Controlled Trial of Rituximab and Cost‐Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome

Simon Bowman, Colin Everett, John O’Dwyer et al. · Arthritis & Rheumatology · 2017 · 264 citations · Full text

Medicine, Immunology, Pharmacotherapy +14

A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren’s Syndrome

Katherine James, Shereen Al-Ali, Jessica Tarn et al. · PLoS ONE · 2015 · 178 citations · Full text

Life Sciences, Bioinformatics, Immunology +17

Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica

Andrew Hutchings, Jane Hollywood, Donna L. Lamping et al. · Arthritis Care & Research · 2007 · 146 citations

Medicine, Internal Medicine, Musculoskeletal Medicine +13